SIRPA and glioblastoma: By targeting the CD47-SIRPα immunological checkpoint glioblastoma development can be inhibited and the activity of phagocytic, dendritic and T-lymphocytes enhanced promoting clearance of tumour cell in innate and adaptive immunity [290,291,292,293].